Earlier findings have identified the requirement of insulin signaling on maturation and the translocation of serotonin (5-HT) transporter, SERT to the plasma membrane of the trophoblast in placenta. Because of the defect on insulin receptor (IR) in the trophoblast of the gestational diabetes mellitus (GDM)-associated placenta, SERT is found entrapped in the cytoplasm of the GDM-trophoblast. SERT is encoded by the same gene expressed in trophoblast and platelets. Additionally, alteration in plasma 5-HT levels and the 5-HT uptake rates are associated with the aggregation rates of platelets. Therefore, here, we investigated a novel hypothesis that GDM-associated defects in platelet IR should change their 5-HT uptake rates, and this should be a leading factor for thrombosis in GDM maternal blood. The maternal blood and the placentas were obtained at the time of cesarean section from the GDM and non-diabetic subjects (n ‫؍‬ 6 for each group), and the platelets and trophoblasts were isolated to determine the IR activity, surface level of SERT, and their 5-HT uptake rates.
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sequently, identifying the mechanisms regulating post-translational modifications are critical for understanding SERT conformations and oligomerization in biological processes and diseases.
As reported earlier, we demonstrated that insulin receptor (IR) in the trophoblast of GDM-placentas is impaired. Consequently, SERT which requires insulin signaling to dissociate from the endoplasmic reticulum (ER) proteins is entrapped at ER. Therefore, the 5-HT uptake rates of trophoblast cells in GDM are decreased (38) . In different tissues, SERT is encoded by a single copy gene for all tissues (20,40 -42) . The SERT mRNA is alternatively spliced, and the splice variants are equally expressed in human placental cells and platelets (43) where it regulates the levels of 5-HT in plasma as well as in platelets. Alterations in the plasma versus platelet 5-HT ratio are associated with thrombosis and vascular resistant at the placental chorionic plate and stem villous vessels (44 -48) . 3 The present study was aimed to investigate whether SERT in platelets is differentially regulated in platelet by determining the 5-HT system and the platelet function in GDM. First the platelet aggregation rates in GDM and non-diabetic maternal blood were analyzed. Interestingly, GDM-platelets responded to their insulin treatment, and the 5-HT uptake rates were upregulated suggesting the differential regulation of SERT trafficking in trophoblast versus platelets. Additional studies on the GDM-associated defect in phosphorylation of IR and the downstream elements was only found in placental trophoblast, but not in the maternal platelets. Here, for the first time we show that in GDM-trophoblast and in GDM-platelets the IR exhibits a differentially response to the impaired insulin level; perhaps due to the cell-type specific binding properties of IR.
Materials and Methods
Subjects-Placentas, cord, and maternal blood samples from 18-year-old or older pregnant women with normal (n ϭ 5) or diagnosed with GDM (n ϭ 5) were recruited for this study. Our study was carried out after an approval from the University of Arkansas for Medical Sciences (UAMS) IRB, which included these procedures, and for which subjects had previously provided written informed consent form. The health conditions of subjects were followed by their physicians (38) . Inclusion and exclusion criteria were evaluated by review of medical history, interviewing the subject, and/or results of routine tests performed for the purpose of clinical care.
Isolation and Purification of Trophoblast-Trophoblast cell isolation and preparation were performed as described previously (38, 39, 49, 59 -61) . Briefly, each cotyledon of a placenta has been dissected, collected, and rinsed with sterile 0.9% NaCl solution. Placenta tissues were digested with DNase, Dispase, and Trypsin containing CMF Hank's. Trophoblasts were then purified under 5-70% gradient solution. Human HLA class I ABC Ab containing Dynabeads were incubated with trophoblast to negatively purify contaminations. Trophoblast cell purify is determined via intracellular cytokeratin-7 (CK-7) Ab and trophoblast membrane protein NDOG1 Ab.
Blood Handling and Platelet Isolation-Maternal blood sample has been obtained from University of Arkansas for Medical Sciences (UAMS) OBGYN department. Blood were maintained in 3.8% sodium citrate solution tube to avoid platelet aggregation and activation. Platelet-rich plasma was prepared by adding 1/2 volume of Tyrode's HEPES buffer to maternal blood and centrifuged at 1.0 ϫ 10 3 rpm for 10 min. In each assay, a dilution of 100,000/l of platelet in blood was applied.
Stirred Platelet Aggregation-For aggregation assays, platelets in plasma were prepared, and platelet counts were normalized (300,000/l) using a Hemavet 950 (Drew Scientific, Waterbury, CT). The response to collagen (3 g/ml) as a platelet agonist was monitored by light transmittance (Chrono-log Corp., Havertown, PA) (55).
Flow Cytometry-The level of platelet activation was assessed using FITC-labeled P-selectin Ab (BD Pharmingen, Cat 553744). Platelets (300,000/l) were incubated in Ab and at the end of the incubation, 300 l of 2% formaldehyde in PBS was added to stop the reaction.
The level of SERT proteins on the PM of platelets (300,000 platelets/assay) was determined using a special Ab, which is designed by our group and generated by Proteintech Group, Inc. (Chicago, IL) against a synthetic peptide corresponding to the second extracellular loop of SERT (38) . The samples were gated for single platelets based on forward and side scatter profiles, and 20,000 events were recorded and read at the UAMS Flow Cytometry Core Facility.
Immunoprecipitation (IP) and Western Blotting (WB) Analysis-Trophoblast (1.5 ϫ 10 6 cells per IP assay) were lysed in IP buffer (55 mm triethylamine (pH 7.5), 111 mm NaCl, 2.2 mm EDTA, 0.44% SDS, 1% Triton X-100) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor mixture (PIM) as previously described (38) . Initially, the cell lysate was incubated with protein A-Sepharose beads to eliminate nonspecific interaction (preclear). Anti-SERT monoclonal (Mab technology, Stone Mountain, GA) Ab, was conjugated to protein A beads for 2 h prior to incubating together with pre-cleared cell lysates overnight at 4°C.
WB analysis was done the next day using anti-IR Ab (Santa Cruz Biotech, Santa Cruz, CA) phospho-AKT (Thr-308), and phosphor-S6K (Thr-229)-Abs (Cell Signaling, Danvers, MA) or monoclonal phospho-tyrosine for primary Ab (eBioscience, San Diego, CA). Horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-mouse was used as the secondary Ab. VersaDoc 1000 gel visualization and analysis system was applied to analysis of densitometry of individual bands.
5-HT Uptake Assay-Trophoblasts (2.3 ϫ 10 5 cells per transport assay) and platelets (300,000/l of platelet in blood) were washed with PBS solution containing 0.1 mM CaCl 2 and 1 mM MgCl 2 . The intact cells were quickly incubated with 14.6 nM [ 3 H]5-HT at room temperature for 10 min. Whatman GF/B filters collected the cells after incubation, and excess solution was filtrated through a funnel. The uptake assay was stopped by washing twice with ice-cold PBS solution. The sample containing filters were placed into scintillation vials for counting. 2␤-carbomethoxy-3-trophane (␤-CIT) (Chemical Synthesis Service, NIMH) was used as a negative control background (22) . 
Results

5-HT Uptake Rates of Trophoblasts and Platelets-Tropho-
blasts were isolated and purified from human term non-diabetic and GDM-associated placentas as previously described (38) . The 5-HT uptake rates of trophoblast were measured in the same number of cells (2.3 ϫ 10 5 ) per group (GDM or nondiabetic) and repeated in quintuplicate of 6 different preparations of trophoblast ( Fig. 1) . Under GDM conditions, the 5-HT uptake rates of GDM trophoblast was determined at 33% lower than the trophoblast of non-diabetic placenta (p Ͻ 0.01).
Next, we evaluated whether platelet 5-HT uptake rates were lower in maternal blood samples of GDM groups than in nondiabetic groups. Platelets were isolated from the maternal and cord blood samples, and their 5-HT uptake rates were measured (Fig. 1 ). No significant difference was found between the uptake rates of platelets of cord blood or of maternal blood of non-diabetic subjects compared with platelets of the blood samples from GDM.
Platelet SERT regulates the plasma versus platelet 5-HT ratio, which plays an important role in 5-HT driven blood pathophysiology and platelet biology. Therefore, platelet aggregation rates were evaluated in maternal and cord blood, also between non-diabetic and GDM pregnant blood samples. Platelets (300,000/l) were stimulated with collagen (3 g/ml) to monitor their behavior in a stirred platelet aggregometer ( Fig. 2A) . Isolated platelets from GDM-maternal or -cord showed a similar aggregation response to collagen than the platelets from maternal and cord blood of non-diabetic pregnancies ( Fig. 2A) . Aggregation rates were on average 79% in platelets from the maternal blood samples (78.6 Ϯ 7.0% in normal versus 77.5 Ϯ 5.0% in GDM; n ϭ 6 each). Aggregation rates appeared as an average of 85% in platelets from the cord blood samples (85 Ϯ 6% in normal versus 90 Ϯ 4% in GDM; n ϭ 6 each).
Platelets (300,000/l) from normal and GDM maternal and cord blood samples were then examined for a marker of platelet activation, P-selectin. Fig. 2B shows no significant difference in the expression of surface P-selectin between platelet plasma membranes of normal and GDM maternal (5 Ϯ 2 in normal versus 6 Ϯ 2 in GDM; n ϭ 6 each) and cord blood samples (6.6 Ϯ 1.0 in normal versus 7.6 Ϯ 2.0 in GDM; n ϭ 6 each). While the 5-HT uptake rates of GDM trophoblast were reduced, the GDM platelet uptake rates appeared unaffected by the diabetic condition.
Defective Insulin Signals in GDM Trophoblasts but Not in GDM Platelets-Given that membrane trafficking of SERT is linked to insulin action in the placenta (38), we investigated the insulin signaling pathways in platelets from non-diabetic and GDM subjects. Insulin binding to its receptor leads to activation of the insulin signaling pathway, by insulin receptor (IR) auto-phosphorylation on cytoplasmic tyrosine residues. To investigate this pathway formally, we determined the basal phosphorylation levels of IR in trophoblast by immunoprecipitation (IP) assays (1.5 ϫ 10 6 cells per assay). While the expression levels of IR in trophoblast were not altered between nondiabetic and GDM samples (Fig. 3A, left middle panel) , the level of basal (non-stimulated) phosphorylated IR was 65.9% lower in GDM-than non-diabetic-trophoblast cells (Fig. 3A , top, and 3B). The cell lysate of each sample was blotted for total actin as the loading control (Fig. 3A, bottom panel) . On the other hand, neither the expression levels nor the phosphorylation levels of IR in platelets from GDM blood samples appeared different compared with platelets derived from non-diabetic maternal blood samples (Fig. 3A, right and 3B ). These findings strongly suggest that under basal (non-insulin-stimulated) conditions, the IR in GDM trophoblast has a lower auto-phosphorylation state despite a normal content of IR, while platelets in GDM are unaffected and platelets respond differentially to insulin. IR expression was evaluated between non-diabetic (n ϭ 7) and GDM (n ϭ 6) trophoblasts to illustrate the deviations among the patients.
In addition to IR auto-phosphorylation, the insulin molecule activates IR substrates (IRS), which initiate the phosphorylation of downstream elements such as AKT, mTOR, and S6K (50). 5 per assay) isolated from non-diabetic and GDM placentas or in platelets (100K/l) isolated from maternal and cord blood (all groups n ϭ 6) were measured as described previously (61) . Rate of uptake is expressed as the means and STD values of quintuplicate determinations from six independent samples in each group. The (*) represents the results of a two-tailed Student's t test with p Ͻ 0.001 (compared with non-diabetic trophoblast uptake rates).
Therefore, in verifying our findings on IR in trophoblast and platelets, we investigated the phosphorylation of IR downstream effectors in platelets and trophoblast of non-diabetic and GDM placental and blood samples.
WB (n ϭ 3-4) analysis of the trophoblast (1.5 ϫ 10 6 cells per WB assay) from GMD and non-diabetic placenta for AKT and S6K was performed. In GDM-trophoblast, the levels of phosphorylation on AKT (Fig. 4, A and B) and S6K (Fig. 4, A and C) were lower, 28.5 and 71.4%, respectively, than their levels in the trophoblast cells of non-diabetic placentas, consistent with the reported studies (7) (8) (9) . These data complement our findings of the phosphorylation of IR in GDM-trophoblast (Fig. 3 ). In contrast to the findings with trophoblast, platelets showed no significant change in the levels of phosphorylation for AKT and S6K between the Normal and GDM blood samples (Fig. 4,  A-C) .
In summary, the 5-HT uptake rates as well as the insulin signaling and downstream elements are specifically down-regulated in the trophoblast of GDM-placentas but not in GDMassociated platelets.
Differential Response of IR to Insulin between Trophoblast and Platelet-The impact of insulin on the level of IR phosphorylation was investigated in trophoblast isolated from non-diabetic and GDM placentas and then starved for insulin first and In response to stimulation with 3 g/ml collagen, platelets from maternal or cord blood samples of GDM subjects showed no significant difference in aggregation rates than the platelets from non-diabetic (control) subjects. All assays were performed in triplicate (n ϭ 7 group). B, surface expression of p-Selectin was determined by flow cytometry as indices of platelet activation. Flow cytometry revealed no significant difference in expression levels of p-Selectin between platelets of nondiabetic or GDM-associated pregnant subjects nor between maternal and cord blood samples. Assays in A and B were performed in triplicate. then treated with various concentration (0, 10, or 100 nM) of insulin for 24 h. The IR expression and the level of phosphorylation were investigated in these trophoblast with IP assay (Fig. 5) . In nondiabetic; but not in GDM-trophoblast, phosphorylation of IR was up-regulated by 15 or 23% with 10 or 100 nM insulin treatment, respectively; while IR expression levels were not affected by these treatments (Fig. 5 ). These findings demonstrate that IR phosphorylation levels show an insulin concentration-dependent pattern. However, the GDM-trophoblast under the same treatment, the level of IR phosphorylation did not show a similar response to the insulin pretreatment. Therefore, the impact of insulin on the level of SERT on plasma membrane of trophoblast and their 5-HT uptake rates were further studied in both non-diabetic trophoblast and platelets.
Next, we tested the 5-HT uptake rates of trophoblast in response to the insulin signaling. Specifically here, we tested if the lower 5-HT uptakes rates of GDM-trophoblast is due to the lack of insulin signaling or defective IR on trophoblast. Equal number of trophoblast (1.5 ϫ 10 6 cells per assay) isolated and purified from GDM-or non-diabetic-placentas were treated with various concentration of insulin and the 5-HT uptake rates were determined (n ϭ 4). The up-regulatory effect of insulin on the levels of SERT molecules at the plasma membrane of trophoblast was only found in non-diabetic trophoblast (Fig. 6) indicating the defect on IR is independent of the insulin level.
In comparing the 5-HT systems in both tissue, placental trophoblast, and platelets by the functional efficiency of IR, next, 6 cells) isolated and purified from non-diabetic and GDM-associated placentas; they were first starved for insulin and then treated with 0, 10, 100 nM insulin for 24 h. After the incubation time, IP assay was performed with polyclonal IR-Ab and WB with pTyr-Ab to determine the level of phosphorylation in each group of cells. The levels of IR were not changed by insulin treatment or between non-diabetic and GDM samples. However, the levels of phospho-IR were elevated in non-diabetic-, but not in GDM-trophoblast, in parallel to the insulin concentration; the highest level of IR phosphorylation was found in non-diabetic-trophoblast pretreated with 100 nM insulin. The results of WB analysis are the summaries of combined data from four densitometric scans of pTyr.
the impact of insulin treatment on 5-HT uptake rates of platelet isolated from non-diabetic and GDM blood samples was investigated (Fig. 7A) . The 5-HT uptake rates of both platelets, nondiabetic and GDM, showed a transient increase (45%) peaking at 10 nM and 20 nM of insulin treatment, compared with the uptake rates of the non-treated platelets (Fig. 7A) .
To validate this transient increase in 5-HT uptake, the levels of SERT at the platelet surface was determined after insulin treatment at different concentrations (Fig. 7B) . The peak level of SERT expression at the surface of platelets was also obtained after 10 nM insulin exposure (increased by 37%), compared with the level of SERT on the surface of the non-treated platelets (Fig. 7B) . Therefore, insulin, specifically at 10 nM and 20 nM concentrations, induces an increase of the 5-HT uptake rates as well as of the surface level of SERT molecules on platelets isolated from non-diabetic and GDM blood samples, respectively.
Discussion
The cell signaling is a cell type-dependent physiological phenomena which occurs by the activation of the receptor but is orchestrated by various, extracellular and intracellular, factors. Errors in the processing of the cellular information cause diseases such as GDM where the processing of the insulin signaling is not transduced due to the defective IR. Although IR is expressed in all tissues, it is still not known if diabetes affects IR equally in all tissues. Here, our findings show that in GDMtrophoblast, the IR is defective while in GDM-platelets IR is functionally active, yet patients are identified as diabetic.
Recently, we reported that insulin facilitates the dissociation of SERT from its chaperone ERp44 and its translocation to the plasma membrane (38) . However, under GDM-associated defects in insulin signaling, SERT is entrapped at the ER and therefore decreases the 5-HT uptake rates in human placental trophoblast cells. While placental SERT function is affected, the platelet SERT functions normal by the lack of insulin in GDM. Various studies demonstrated the expression of ER proteins in blood plasma (51) . Therefore, in platelet the trafficking of SERT to the plasma membrane should not be through ERp44-dependent manner as demonstrated in placental trophoblast.
Platelets are derived from the fragmented cytoplasm of megakaryocytes and enter the circulation in an inactive form. The activation of platelets enlists more platelets at a fibrinstabilized hemostatic area to form a thrombus after associating with the endothelium or each other. As is the case for many membrane proteins, SERT trafficking in platelet is mediated by vesicular packing and interactions with specialized proteins. Upon clearance of 5-HT from plasma to platelet, SERT is translocated from the plasma membrane to be routed elsewhere. The post-translational modification of SERT regulates transporter function (22, 24, 27-29, 31, 45-48) , 3 but given that glycosylation occurs in megakaryocytes, (i.e. the progenitors of platelets); this aspect of SERT regulation may not be altered in FIGURE 6 . The impact of insulin treatment on 5-HT uptake rates of trophoblast. Trophoblasts (1.2 ϫ 10 6 ) isolated and purified from non-diabetic and GDM-placenta were initially incubated with 0, 10, 20, or 100 nM insulin. Next day, their 5-HT uptake rates were measured as described previously (44) . Asterisks represent the results of a two-tailed Student's t test with p Ͻ 0.001. (*) indicates statistical difference in 5-HT uptake rates between non-diabetic and GDM-trophoblast; (**) shows that elevation in the 5-HT uptake rates by 10 nM insulin are significantly higher than the control samples. FIGURE 7. The impact of insulin treatment on 5-HT uptake rates of platelets. A, platelets isolated from the non-diabetic-or GDM-associated maternal blood samples. Platelets were incubated with 0 -100 nM insulin overnight, followed with 5-HT uptake assay as described previously (n ϭ 3) (44) . Asterisks represent the results of a two-tailed Student's t test with p Ͻ 0.001; (*) and (**) show the elevation in the 5-HT uptake rates by insulin treatment of nondiabetic or GDM-platelets, respectively compared with their untreated counterparts. B, platelets were prepared from non-diabetic and GDM-maternal blood. Following an overnight treatment with (0 -100 nM) insulin, plasma membrane expression of SERT was determined by flow cytometry (55) . Mean fluorescence intensity of SERT expression in platelets (300,000 platelets/per assay) isolated from non-diabetics was at similar levels but both groups show a significant elevation in insulin treatment. Flow cytometry revealed a decrease of 51% in the expression levels of SERT in trophoblast of GDM placentas. Asterisks represent the results of a two-tailed Student's t test with p Ͻ 0.001; (*) and (**) show the elevation in the expression of SERT on platelet surface by insulin treatment of non-diabetic or GDM-platelets, respectively compared with their untreated counterparts.
platelets. In platelets, the biosynthesis as well as the post-translational modifications of proteins is minimal.
The clinical and biochemical findings infer a complex process to the role of plasma 5-HT in platelet adhesion, aggregation, and thrombus formation. An elevation in free 5-HT levels in plasma accelerates the exocytosis of dense and ␣-granules (52, 53); in turn, these secrete more 5-HT along with the ␣-granules-located procoagulant molecules that will mediate hemostasis. Supporting these hypotheses is the fact that platelets of 5-HT infused mice, in the absence of cardiovascular problem, show an enhanced aggregation profile; however, when the 5-HT-infused mice were injected with a selective 5-HT reuptake inhibitor (SSRI) (54, 55) or a 5-HT 2A antagonist (54, 56 ) the affect of elevated free 5-HT levels in plasma was reversed, and the platelet aggregation profile normalized (52) (53) (54) (55) (56) (57) . The importance of the plasma 5-HT level and platelet SERT in the platelet aggregation phenomenon is supported by findings in platelets of mice lacking the gene for TPH1 (54, 57) or the gene for SERT (54) : where granular secretion rates as well as the risk of thrombosis are significantly reduced (54, 55, 57) .
Since the trafficking of SERT to the plasma membrane of trophoblast is regulated by its association with ERp44 in an insulin-dependent manner (38) and this pathway is not affective in platelet (51), the 5-HT uptake rates as well as the level of SERT on the cell surface in GDM-platelet are at the same level as those in non-diabetic-platelets. More important than this, the IR and the downstream elements such as Akt and S6k are functionally active in GDM-platelet whereas they are inactive in GDM-trophoblast. We hypothesize that diabetes affects IR differently in placenta then in platelets. In turn, the response to insulin signaling appears in a cell type-dependent characteristic. In a separate study (58) , we showed the occurrence of the incidence of intervillous thrombi (IVT) is significantly higher in diabetes-associated placentas, particularly in GDM within the absence of the thrombosis in maternal blood. IR in placenta is defected by the GDM but not IR in platelets, which results in a local placental pathology (IVT) but not systemic pathology (thrombosis) in GDM.
IR responses to insulin signaling in trophoblast is important for the role of trophoblast in placenta. Because they function as endothelium, they are also metabolically active cells of placenta. So they have transport ability as well as the hormone secretion. Therefore, defects in insulin signaling have several impact factors on the integrity of placenta to the growing embryos.
In the current study, first, we compared the phosphorylation levels of IR and its downstream elements, AKT and S6K to trophoblast and platelets prepared from non-diabetic and GDM-placentas and -blood samples, respectively. Initial findings showed that IR and the downstream elements were downregulated in GDM-trophoblast but not in GDM-platelets. Then, we verified these conclusions by stimulating the normaltrophoblast with insulin to determine if the phosphorylation levels of IR would be altered and if this would be in a concentration-dependent manner. While insulin treatment elevates the level of phospho-IR in trophoblasts, it did not change that in platelets. Therefore, all insulin and platelet versus trophoblastrelated findings fit together well with the surface expression and the 5-HT uptake rates of these tissues. Because of the defect in GDM-trophoblast, but not in GDM-platelets, IR cannot respond to the insulin signaling. The impaired insulin signaling arrests SERT in ER of GDM-trophoblasts; however, in GDMplatelets, SERT molecules are translocated to the plasma membrane in a good order. Based on our published and current studies we hypothesize that the defective IR on GDM-trophoblast could be a part of the IVT formation in placenta, but the functional IR on GDM-platelet prevents the formation of systemic thrombosis in the maternal blood. 
